Insider Selling: Vor Biopharma (NYSE:VOR) Major Shareholder Sells 464,421 Shares of Stock

Key Points

• Reprogrammed Interchange LLC, a major shareholder of Vor Biopharma, sold 464,421 shares on September 8 for approximately $924,197, resulting in a 1.31% decrease in their ownership.
• The stock price of Vor Biopharma has recently declined, closing at $1.80 on Wednesday, with a significant trading volume of over 6 million shares.
• Hedge funds have been increasing their positions in Vor Biopharma, with institutions owning 97.29% of the stock, indicating strong institutional interest despite recent shareholder sales.

Vor Biopharma Inc. (NYSE:VOR - Get Free Report) major shareholder Reprogrammed Interchange Llc sold 464,421 shares of the stock in a transaction that occurred on Monday, September 8th. The shares were sold at an average price of $1.99, for a total transaction of $924,197.79. Following the completion of the transaction, the insider owned 35,012,518 shares of the company's stock, valued at $69,674,910.82. This trade represents a 1.31% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Major shareholders that own more than 10% of a company's shares are required to disclose their transactions with the SEC.

Reprogrammed Interchange Llc also recently made the following trade(s):

• On Wednesday, September 10th, Reprogrammed Interchange Llc sold 350,000 shares of Vor Biopharma stock. The stock was sold at an average price of $1.82, for a total transaction of $637,000.00.
• On Tuesday, September 9th, Reprogrammed Interchange Llc sold 449,226 shares of Vor Biopharma stock. The shares were sold at an average price of $2.00, for a total transaction of $898,452.00.
• On Friday, September 5th, Reprogrammed Interchange Llc sold 400,000 shares of Vor Biopharma stock. The stock was sold at an average price of $1.97, for a total transaction of $788,000.00.
• On Thursday, September 4th, Reprogrammed Interchange Llc sold 453,016 shares of Vor Biopharma stock. The shares were sold at an average price of $1.93, for a total transaction of $874,320.88.
• On Wednesday, September 3rd, Reprogrammed Interchange Llc sold 554,612 shares of Vor Biopharma stock. The shares were sold at an average price of $2.00, for a total transaction of $1,109,224.00.
• On Thursday, August 28th, Reprogrammed Interchange Llc sold 806,351 shares of Vor Biopharma stock. The shares were sold at an average price of $2.01, for a total transaction of $1,620,765.51.
• On Wednesday, August 27th, Reprogrammed Interchange Llc sold 611,647 shares of Vor Biopharma stock. The shares were sold at an average price of $2.01, for a total transaction of $1,229,410.47.
• On Tuesday, August 26th, Reprogrammed Interchange Llc sold 284,190 shares of Vor Biopharma stock. The stock was sold at an average price of $2.08, for a total transaction of $591,115.20.
• On Monday, August 25th, Reprogrammed Interchange Llc sold 387,346 shares of Vor Biopharma stock. The stock was sold at an average price of $2.12, for a total transaction of $821,173.52.

Vor Biopharma Stock Performance

Shares of Vor Biopharma stock traded down $0.21 on Wednesday, reaching $1.80. 6,041,745 shares of the stock were exchanged, compared to its average volume of 7,646,274. The firm's 50 day moving average is $2.12 and its 200-day moving average is $1.12. Vor Biopharma Inc. has a one year low of $0.13 and a one year high of $3.29. The firm has a market cap of $228.03 million, a PE ratio of -1.09 and a beta of 2.05.

Hedge Funds Weigh In On Vor Biopharma

Hedge funds have recently modified their holdings of the business. Two Sigma Investments LP raised its position in shares of Vor Biopharma by 18.9% during the 4th quarter. Two Sigma Investments LP now owns 163,064 shares of the company's stock worth $181,000 after acquiring an additional 25,930 shares in the last quarter. Money Concepts Capital Corp grew its position in Vor Biopharma by 106.1% during the first quarter. Money Concepts Capital Corp now owns 51,535 shares of the company's stock valued at $37,000 after acquiring an additional 26,535 shares during the period. XTX Topco Ltd acquired a new position in shares of Vor Biopharma in the second quarter worth about $66,000. Northern Trust Corp raised its position in shares of Vor Biopharma by 39.0% during the 4th quarter. Northern Trust Corp now owns 157,617 shares of the company's stock worth $175,000 after purchasing an additional 44,252 shares during the period. Finally, Goldman Sachs Group Inc. boosted its stake in shares of Vor Biopharma by 218.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 84,945 shares of the company's stock worth $61,000 after acquiring an additional 58,247 shares in the last quarter. 97.29% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

VOR has been the subject of several recent research reports. HC Wainwright reiterated a "buy" rating and issued a $3.00 target price on shares of Vor Biopharma in a research note on Thursday, August 14th. Wedbush restated an "outperform" rating on shares of Vor Biopharma in a research note on Thursday, June 26th. Five analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $6.07.

Vor Biopharma Company Profile

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.